Hyaluronidase / rituximab Alternatives Compared
| Hyaluronidase / rituximab | Imbruvica (ibrutinib) | Brukinsa (zanubrutinib) |
|
|---|
| Hyaluronidase / rituximab | Imbruvica (ibrutinib) | Brukinsa (zanubrutinib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. Hyaluronidase / rituximab may also be used for purposes not listed in this medication guide. |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Prescribed for Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. Brukinsa may also be used for purposes not listed in... View more |
||||||||
| More about Hyaluronidase / rituximab | More about Imbruvica (ibrutinib) | More about Brukinsa (zanubrutinib) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Imbruvica has an average rating of 6.6 out of 10 from a total of 69 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Brukinsa has an average rating of 8.6 out of 10 from a total of 45 ratings on Drugs.com. 78% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
View all Imbruvica side effects |
View all Brukinsa side effects |
|||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Brukinsa prices |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
|
||||||||
| Brand Names | ||||||||||
| Rituxan Hycela |
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
648 hours (empirically) |
6 hours |
4 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 286 drugs are known to interact with Hyaluronidase / rituximab:
|
A total of 508 drugs are known to interact with Imbruvica:
|
A total of 529 drugs are known to interact with Brukinsa:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
June 22, 2017 |
November 13, 2013 |
November 14, 2019 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.